Brief: Barinthus Bio Announces Data From Phase 1B/2 Apollo Trial Of Vtp-200 In Persistent HPV Infections
18/04/2024 21:36
April 18 (Reuters) - Barinthus Biotherapeutics PLC
2ABy.F :
* BARINTHUS BIO ANNOUNCES TOPLINE DATA FROM PHASE 1B/2
APOLLO
TRIAL OF VTP-200 IN PERSISTENT HIGH-RISK HUMAN PAPILLOMAVIRUS
(HPV) INFECTIONS
* BARINTHUS BIOTHERAPEUTICS PLC: PRIMARY SAFETY ENDPOINT
MET;
VTP-200 WAS GENERALLY WELL-TOLERATED
* BARINTHUS BIOTHERAPEUTICS PLC - PRIMARY SAFETY ENDPOINT
MET;
VTP-200 WAS GENERALLY WELL-TOLERATED
* BARINTHUS BIOTHERAPEUTICS: DIDN'T OBSERVE IMPROVEMENT FROM
VTP-200 IN OVERALL POOLED RESULTS, DID OBSERVE POSITIVE TRENDS
IN HIGHEST DOSE COHORTS
Source text for Eikon: ID:nGNX9QktJS
Further company coverage: 2ABy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing